Breaking News:
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus“ in diese Kupferaktie investierte
Anzeige
INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion
15,15 EUR
+1,19 %+0,18
7. Nov, 13:39:54 Uhr,
Lang & Schwarz
Kommentare 427
H
HaveYouMetTed?,
29.06.2021 19:51 Uhr
0
Also fallende Kurse bald? KE ist ja immer zumindest kurzfristig mit fallenden Kursen verbunden …?
D
DAKo,
28.06.2021 23:08 Uhr
0
Kapitalerhöhung wenn ich das richtig verstehe.
Summer.76,
28.06.2021 22:20 Uhr
0
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
https://www.globenewswire.com/news-release/2021/06/28/2254252/0/en/Intellia-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
...announced today that it has commenced an underwritten public offering of $400 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia. ...
JeromePower,
28.06.2021 14:08 Uhr
0
👀
Summer.76,
28.06.2021 13:28 Uhr
2
HC Wainwright hat schon mal das Kursziel ordentlich angepasst:
Intellia Therapeutics Price Target Raised to $171.00/Share From $111.00 by HC Wainwright & Co.
https://www.benzinga.com/stock/NTLA/ratings
C
C10H12N2O,
28.06.2021 13:13 Uhr
0
Was meint ihr? Steigt der Kurs mit den Amerikanern weiter, oder nehmen sie wohl erstmal Gewinne mit?
og_pipo,
28.06.2021 12:58 Uhr
0
Wat is das denn?
Luistrenker,
28.06.2021 11:53 Uhr
0
....Mal gespannt wie die Amis reagieren 🤔
D
DAKo,
28.06.2021 10:23 Uhr
0
Wow...seit 3 Monaten auf der WL...ich bin gespannt was noch kommt. Den Einstieg hab ich aber verpasst
Hansmuller,
28.06.2021 10:19 Uhr
0
läuft
Börsenwurst,
28.06.2021 9:05 Uhr
0
Ein Durchbruch in der Genomic💪
Summer.76,
26.06.2021 18:54 Uhr
0
👍👍
B
BobbyBobberson,
26.06.2021 17:26 Uhr
0
Ließt sich gut ✌️
B
BobbyBobberson,
26.06.2021 17:26 Uhr
3
https://www.prnewswire.com/news-releases/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-causing-protein-after-single-infusion-of-ntla-2001-an-investigational-crispr-therapy-for-transthyretin-attr-amyloidosis-301320471.html
Summer.76,
25.06.2021 15:44 Uhr
0
This Biotech Is Editing Genes Inside the Body. What It Means for the Stock.
https://www.barrons.com/articles/this-biotech-is-editing-genes-inside-the-body-what-it-means-for-the-stock-51624562859?mod=hp_LEADSUPP_3
Gene-editing startups have captured the attention—and wallets—of Wall Street.
They’re powered by the Nobel Prize-winning technique known as Crispr-Cas9, and an important test of the technology’s value is coming Saturday.
Intellia Therapeutics and partner Regeneron Pharmaceuticals will share the world’s first data from a Phase 1 trial of a therapy that edits flawed genes inside the body.
The treatment, developed by Intellia with Regeneron’s backing, turns off a mutant gene that drives liver cells to make a harmful protein that damages the heart and nerves. The disease, known as transthyretin amyloidosis, or ATTR, is treatable now only with drugs.
Encouraging numbers from the Phase 1 trial would vindicate the investors who bid up Intellia stock (ticker: NTLA) some 275% in the past year. By comparison, the Nasdaq Composite rose about 40% and Regeneron (REGN) lost 17% as excitement about its Covid-19 antibody products waned.
...
“This will be a big catalyst for the whole field of gene editing,” said Luca Issi, an analyst at RBC Capital Markets who is betting the data will be positive. He launched coverage of Intellia in May with an Outperform rating.
Issi prefers Intellia over peers Crispr Therapeutics (CRSP) and Editas Medicine (EDIT) because of its lead in editing genes inside the body. Editas actually launched the first clinical trial of an in-body technique, but is targeting a rare eye disorder in its first clinical trial and won’t report its data until later this year. Crispr Therapeutics has treated more patients in its clinical trials than both Intellia and Editas, but those therapies— for cancer and sickle-cell disease—are performed outside the body: A patient’s cells are harvested, edited in a lab, then reinfused.
For Issi, Intellia needs to deliver results that show its therapy is safe and at least 80% effective in cutting the harmful protein. If the rate is that high, he thinks the treatment will be judged a worthy alternative to current drugs. Infusions of Alnylam products can reduce the harmful protein by over 80%. Pfizer’s pills render some of the protein harmless, slowing the damage done by the disease.
If Intellia delivers an impressive number, Issa thinks the stock could jump 50% from recent levels around $85. A successful one-time treatment could be priced above $1 million, Issa believes, with annual sales surpassing $2 billion a decade from now. If investors come around to his way of thinking, the analyst sees Intellia stock worth $110 within a year.
Guggenheim’s Debjit Chattopadhyay also thinks Intellia has to match or top Alnylam’s 80% to pose a real challenge.
...
Summer.76,
24.06.2021 14:55 Uhr
0
https://www.globenewswire.com/news-release/2021/06/24/2252489/0/en/Intellia-Therapeutics-Names-James-Basta-J-D-as-Executive-Vice-President-General-Counsel-and-Corporate-Secretary.html
Intellia Therapeutics ernennt James Basta, JD, zum Executive Vice President, General Counsel und Corporate Secretary
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | SOLAREDGE TECH Hauptdiskussion | +1,00 % | |
2 | Trading- und Aktien-Chat | ||
3 | Exela 2023 sachliches Forum | -32,83 % | |
4 | MicroStrategy | -0,50 % | |
5 | RHEINMETALL Hauptdiskussion | +5,12 % | |
6 | Dax Prognose | ±0,00 % | |
7 | OCUGEN NEWS | +6,34 % | |
8 | MODERNA INC. DL-,0001 Hauptdiskussion | +8,47 % | |
9 | JUMIA TECH. SP.ADR/2 O.N. Hauptdiskussion | -18,66 % | |
10 | FREYR BATTERY | ±0,00 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | SOLAREDGE TECH Hauptdiskussion | +1,08 % | |
2 | Exela 2023 sachliches Forum | -32,32 % | |
3 | MicroStrategy | -0,50 % | |
4 | RHEINMETALL Hauptdiskussion | +5,10 % | |
5 | OCUGEN NEWS | +6,34 % | |
6 | JUMIA TECH. SP.ADR/2 O.N. Hauptdiskussion | -17,43 % | |
7 | MODERNA INC. DL-,0001 Hauptdiskussion | +8,88 % | |
8 | NVIDIA Hauptdiskussion | -0,10 % | |
9 | SMA SOLAR Hauptdiskussion | -0,25 % | |
10 | FREYR BATTERY | ±0,00 % | Alle Diskussionen |